Tianjin TEDA Biomedical (08189) Announces February 2026 Monthly Return on Movements in Securities
Bulletin Express
Mar 02
Tianjin TEDA Biomedical Engineering Company Limited (08189) reported that its total authorized share capital as of the end of February 2026 remained at RMB213.39 million, reflecting 1.44 billion H shares and 697.50 million domestic shares at a par value of RMB0.1 each.
During the month, the company’s issued H shares stood at 1.44 billion, while domestic shares totaled 697.50 million, with no issuance or cancellation of treasury shares. The public float requirement of a 25% minimum threshold was confirmed as satisfied. No share options, warrants, or convertible securities were outstanding throughout the period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.